Physician profile
Ryan Lahood
NPI 1033607742
$4,834.64
in general payments reported to CMS, 2019-2025
20 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $191 · 2024: $2,493 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659 · Education: $55.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.80 |
| Education | $55.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,227.83 | 2022-2025 | Tezspire, Breztri, Fasenra |
| Genzyme Corporation | $1,183.69 | 2023-2025 | |
| Genentech USA, INC. | $509.13 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $437.44 | 2024-2025 | Cuvitru, Takhzyro, Hyqvia |
| Novartis Pharmaceuticals Corporation | $377.74 | 2024-2025 | |
| Amgen INC. | $213.12 | 2024-2025 | Tezspire |
| Glaxosmithkline, LLC. | $133.57 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $132.09 | 2024-2025 | Haegarda, Hizentra, Andembry |
| Pharming Healthcare, INC. | $120.75 | 2023-2025 | Ruconest |
| Regeneron Healthcare Solutions, INC. | $106.89 | 2024-2025 | Dupixent |
| Abbvie INC. | $85.61 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $55.99 | 2025 | |
| Janssen Scientific Affairs, LLC | $45.68 | 2024 | Tremfya |
| Ars Pharmaceuticals Operations, INC. | $40.04 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $36.89 | 2024-2025 | Orladeyo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.24 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $30.35 | 2025 | Nemluvio |
| Kaleo, INC. | $26.81 | 2024 | Auvi-Q |
| Organon LLC | $25.25 | 2025 | |
| Cycle Pharmaceuticals INC | $14.53 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Lahood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.